COSCIENS Biopharma Inc. Completes Share Capital Amendment
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
CSCI Leverages Technology, Workforce Expansion, and Operational Discipline to Drive Continued Growth Across Florida
COSCIENS Biopharma Inc. Reports Q1 2026 Results
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
COSCIENS Comments on Unusual Market Activity
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
COSCIENS Provides Strategic Update
Meet CSCI: The First Family of Florida Shell Construction
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
Fueled by Precision and Performance, President Daniel Goldburg Leads CSCI Into Its Next Chapter as Florida's Premier Structural Shell Contractor
COSCIENS Biopharma Inc. Announces Leadership Change
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
COSCIENS Biopharma Announces Change to Board of Directors
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency